ATE417065T1 - Hochaffiner ny-eso-t-zellen-rezeptor - Google Patents

Hochaffiner ny-eso-t-zellen-rezeptor

Info

Publication number
ATE417065T1
ATE417065T1 AT05745017T AT05745017T ATE417065T1 AT E417065 T1 ATE417065 T1 AT E417065T1 AT 05745017 T AT05745017 T AT 05745017T AT 05745017 T AT05745017 T AT 05745017T AT E417065 T1 ATE417065 T1 AT E417065T1
Authority
AT
Austria
Prior art keywords
eso
affinity
cell receptor
sllmwitqc
tcrs
Prior art date
Application number
AT05745017T
Other languages
English (en)
Inventor
Jonathan Michael Boulter
Bent Jakobsen
Yi Li
Peter Molloy
Steven Dunn
Original Assignee
Medigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0411123A external-priority patent/GB0411123D0/en
Priority claimed from GB0419643A external-priority patent/GB0419643D0/en
Application filed by Medigene Ltd filed Critical Medigene Ltd
Application granted granted Critical
Publication of ATE417065T1 publication Critical patent/ATE417065T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Secondary Cells (AREA)
AT05745017T 2004-05-19 2005-05-18 Hochaffiner ny-eso-t-zellen-rezeptor ATE417065T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0411123A GB0411123D0 (en) 2004-05-19 2004-05-19 High-affinity NY-ESO T cell receptors
GB0419643A GB0419643D0 (en) 2004-09-03 2004-09-03 High affinity ny-eso t cell receptors

Publications (1)

Publication Number Publication Date
ATE417065T1 true ATE417065T1 (de) 2008-12-15

Family

ID=35428916

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05745017T ATE417065T1 (de) 2004-05-19 2005-05-18 Hochaffiner ny-eso-t-zellen-rezeptor

Country Status (10)

Country Link
US (10) US8143376B2 (de)
EP (1) EP1765860B1 (de)
JP (1) JP4773434B2 (de)
AT (1) ATE417065T1 (de)
AU (1) AU2005245664B2 (de)
CA (1) CA2566363C (de)
DE (1) DE602005011617D1 (de)
DK (1) DK1765860T3 (de)
NZ (1) NZ550810A (de)
WO (1) WO2005113595A2 (de)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033520A2 (en) 2001-09-24 2003-04-24 University Of Pittburgh Of The Commonwealth System Of Higher Education Anticancer vaccine and diganostic methods and reagents
ATE417065T1 (de) 2004-05-19 2008-12-15 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor
EP4023240A1 (de) 2004-07-06 2022-07-06 3D Matrix, Inc. Gereinigte amphile peptid-zusammensetzungen und ihre verwendung
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
WO2007044033A2 (en) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
ATE414718T1 (de) 2005-01-05 2008-12-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
GB0511124D0 (en) * 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
CN105483088B (zh) 2005-10-18 2021-05-28 国家犹太健康中心 条件无限增殖化长期干细胞和制备和使用所述细胞的方法
CN101379083A (zh) * 2005-12-20 2009-03-04 鹿特丹伊拉斯姆斯大学医疗中心 诱导凋亡的蛋白质复合物以及其治疗应用
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008037943A1 (en) * 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors
WO2008038002A2 (en) * 2006-09-29 2008-04-03 Medigene Limited T cell therapies
HUE066143T2 (hu) 2007-06-26 2024-07-28 F Star Therapeutics Ltd Kötõágensek megjelenítése
EP2197910A2 (de) * 2007-09-25 2010-06-23 The United States of America, as represented by the Secretary, Department of Health and Human Services Modifizierte t-zellen-rezeptoren und damit in zusammenhang stehende materialien und methoden
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
ES2820873T3 (es) 2008-05-16 2021-04-22 Taiga Biotechnologies Inc Anticuerpos y su procesos de preparación
WO2010011994A2 (en) 2008-07-25 2010-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polypeptides and uses thereof
ES2681478T3 (es) 2008-08-28 2018-09-13 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
GB0816096D0 (en) * 2008-09-04 2008-10-15 Medigene Ltd Diabetes t cell receptors
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
WO2012013913A1 (en) * 2010-07-28 2012-02-02 Immunocore Ltd T cell receptors
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
WO2013041865A1 (en) * 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
EP2760892A1 (de) 2011-09-29 2014-08-06 Apo-T B.V. Multispezifische bindungsmoleküle zur anzielung aberranter zellen
CA2860914A1 (en) 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
CN110511278B (zh) 2012-05-07 2024-08-09 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
ES2835200T3 (es) 2012-05-22 2021-06-22 Us Health Uso médico de células que comprenden receptores de células T anti-NY-ESO-1
CA3133302A1 (en) 2012-07-20 2014-01-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
SG11201500423TA (en) 2012-07-27 2015-02-27 Univ Illinois Engineering t-cell receptors
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
ES2746240T3 (es) 2013-03-13 2020-03-05 Health Research Inc Composiciones y procedimientos para la utilización de receptores de células T recombinantes para el reconocimiento directo de un antígeno tumoral
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
EP3015477B1 (de) * 2013-06-26 2021-08-18 XLifeSc, Ltd. Hochstabiler t-zell-rezeptor und herstellungsverfahren und anwendung davon
CA2930847A1 (en) 2013-11-22 2015-05-28 Fred Hutchinson Cancer Research Center Engineered high-affinity human t cell receptors
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
RU2722696C2 (ru) * 2014-03-14 2020-06-03 Иммунокор Лимитед Библиотеки tcr
CA2955984A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
WO2016054086A1 (en) * 2014-09-30 2016-04-07 The Regents Of The University Of California Codon-optimized lentiviral vector for stem cell reprogramming
CN107206024B (zh) 2014-10-31 2021-12-03 宾夕法尼亚大学董事会 改变cart细胞中的基因表达及其用途
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
GB201506642D0 (en) * 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
CN106279404A (zh) * 2015-05-20 2017-01-04 广州市香雪制药股份有限公司 一种可溶且稳定的异质二聚tcr
IL302102A (en) 2015-05-20 2023-06-01 Dana Farber Cancer Inst Inc shared neoantigens
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
CA3012607A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Crispr enzymes and systems
IL257105B (en) 2015-07-31 2022-09-01 Univ Minnesota Modified cells and methods of therapy
GB201516272D0 (en) * 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3368689B1 (de) 2015-10-28 2020-06-17 The Broad Institute, Inc. Zusammensetzungen zur modulierung von immunantworten unter verwendung von immunzellgensignaturen
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
HRP20250113T1 (hr) 2016-06-02 2025-03-28 Immunocore Limited Režim doziranja za gp100-specifični tcr - anti-cd3 scfv fuzijski protein
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
US11453726B2 (en) 2016-09-15 2022-09-27 Quadrucept Bio Limited Multimers, tetramers and octamers
WO2018064208A1 (en) 2016-09-28 2018-04-05 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
JP7181862B2 (ja) 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
CN108117596B (zh) 2016-11-29 2023-08-29 香雪生命科学技术（广东）有限公司 针对ny-eso的高亲和力tcr
US12269859B2 (en) 2016-12-02 2025-04-08 Angeles Therapeutics, Inc. Synthetic immune receptors and methods of use thereof
AU2017367730A1 (en) 2016-12-02 2019-06-06 Taiga Biotechnologies, Inc. Nanoparticle formulations
JP7348063B2 (ja) 2017-01-05 2023-09-20 フレッド ハッチンソン キャンサー センター ワクチン効力を改善するためのシステム及び方法
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
CA3049163A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
AU2018207172B2 (en) 2017-01-13 2023-10-12 Mink Therapeutics, Inc. T cell receptors that bind to NY-ESO-1 and methods of use thereof
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3580561B1 (de) 2017-02-12 2023-11-01 BioNTech US Inc. Verfahren und zusammensetzungen auf hla-basis und verwendungen davon
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
PE20200152A1 (es) 2017-03-27 2020-01-17 Hoffmann La Roche Receptores de union a antigeno mejorados
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EP3606518A4 (de) 2017-04-01 2021-04-07 The Broad Institute, Inc. Verfahren und zusammensetzungen zur detektion und zur modulation einer immuntherapieresistenzgensignatur in krebs
EP3610266A4 (de) 2017-04-12 2021-04-21 Massachusetts Eye and Ear Infirmary Tumorsignatur für metastasen, zusammensetzungen von substanzen und verwendung davon
EP3612629A1 (de) 2017-04-18 2020-02-26 The Broad Institute, Inc. Zusammensetzungen zur erkennung von sekretion und verwendungsverfahren
WO2018209324A2 (en) 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
US12297436B2 (en) 2017-05-18 2025-05-13 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN115028739A (zh) 2017-08-03 2022-09-09 泰加生物工艺学公司 用于治疗黑素瘤的方法和组合物
KR102338449B1 (ko) 2017-09-21 2021-12-10 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물
BR112020005675A2 (pt) 2017-09-22 2020-10-20 WuXi Biologics Ireland Limited novos complexos de polipeptideo cd3/cd19 biespecíficos
PH12020550112A1 (en) 2017-09-22 2020-10-26 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes
EP3695408A4 (de) 2017-10-02 2021-12-15 The Broad Institute, Inc. Verfahren und zusammensetzungen zur detektion und modulation einer immuntherapieresistenzgensignatur in krebs
KR20200063215A (ko) 2017-10-06 2020-06-04 오슬로 유니버시테시케후스 에이치에프 키메라 항원 수용체
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
WO2019084427A1 (en) * 2017-10-27 2019-05-02 Kite Pharma, Inc. T-LYMPHOCYTE RECEPTOR ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
EP3710039A4 (de) 2017-11-13 2021-08-04 The Broad Institute, Inc. Verfahren und zusammensetzungen zur behandlung von krebs durch targeting des clec2d-klrb1-wegs
US12171783B2 (en) 2017-11-13 2024-12-24 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
EP3714041A1 (de) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion von peripheren blutlymphozyten (pbls) aus peripherem blut
CN109837245A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种tcr敲除的靶向ny-eso-1的t细胞受体基因修饰t细胞及其制备方法和应用
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CA3085765A1 (en) 2017-12-15 2019-06-20 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US11267864B2 (en) * 2018-02-26 2022-03-08 Medigene Immunotherapies Gmbh Nyeso tcr
US12331095B2 (en) 2018-03-14 2025-06-17 Medigene Immunotherapies Gmbh Inducible T cell receptors and uses thereof
US12090170B2 (en) 2018-04-06 2024-09-17 The Regents Of The University Of California Methods of treating glioblastomas
EP3773632A4 (de) 2018-04-06 2022-05-18 The Regents of The University of California Verfahren zur behandlung von egfrviii-exprimierenden glioblastomen
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2020033923A1 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antigen binding agents that bind cd277 and uses thereof
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
BR112021003631A2 (pt) 2018-09-05 2021-05-18 Glaxosmithkline Intellectual Property Development Limited modificação de célula t
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
EA202191107A1 (ru) * 2018-10-23 2021-09-17 Ридженерон Фармасьютикалз, Инк. T-клеточные рецепторы ny-eso-1 и способы их применения
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020132586A1 (en) 2018-12-21 2020-06-25 Neon Therapeutics, Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
BR112021016875A2 (pt) 2019-03-01 2022-01-04 Iovance Biotherapeutics Inc Processo para expansão de linfócitos de sangue periférico
EP3935151A1 (de) 2019-03-08 2022-01-12 Klinikum der Universität München Anti-csf1r-car-exprimierende lymphozyten für gezielte tumortherapie
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (de) 2019-03-18 2022-01-26 The Broad Institute, Inc. Zusammensetzungen und verfahren zur modulation metabolischer regulatoren der t-zell-pathogenität
CN113906140B (zh) * 2019-03-18 2025-01-28 路德维格癌症研究院 A2/ny-eso-1特异性t细胞受体及其用途
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
AU2020272664A1 (en) 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
AU2020274117A1 (en) 2019-05-14 2021-12-02 Taiga Biotechnologies, Inc. Compositions and methods for treating T cell exhaustion
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
US20210009718A1 (en) 2019-06-25 2021-01-14 Gilead Sciences, Inc. FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
US20220251215A1 (en) * 2019-07-03 2022-08-11 Regeneron Pharmaceuticals, Inc. Anti-new york esophageal squamous cell carcinoma 1 (ny-eso-1) antigen-binding proteins and methods of use thereof
CN112300268B (zh) * 2019-08-02 2023-02-28 香雪生命科学技术（广东）有限公司 识别ny-eso-1抗原的高亲和力t细胞受体
WO2021030182A1 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Bifunctional single variable domain t cell receptors and uses thereof
JP2022545643A (ja) 2019-08-13 2022-10-28 キングス・カレッジ・ロンドン Ｉｌ－１スーパーファミリーのサイトカインの空間時間的に制限された活性が武装化された免疫応答性細胞
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
MX2022009947A (es) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
CN120058957A (zh) 2020-03-30 2025-05-30 国立大学法人三重大学 双特异性抗体
CN111690051B (zh) * 2020-06-28 2021-08-17 英威福赛生物技术有限公司 靶向ny-eso-1(157-165)表位的特异性t细胞受体及抗肿瘤应用
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
CA3207868A1 (en) 2021-02-09 2022-08-18 Xianhui Wu Tcr and application thereof
WO2022183076A1 (en) 2021-02-25 2022-09-01 Lyell Immunopharma, Inc. Enhanced immune cell therapy targeting ny-eso-1
US20240150711A1 (en) 2021-03-01 2024-05-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
WO2023288267A1 (en) 2021-07-14 2023-01-19 2Seventy Bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023021113A1 (en) 2021-08-18 2023-02-23 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
WO2023077028A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Enhanced t cell therapy targeting ny-eso-1
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
EP4452415A1 (de) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Degrader der ikaros-zinkfingerfamilie und verwendungen davon
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US12103971B2 (en) 2022-02-20 2024-10-01 Immunocore Limited HIV specific binding molecules
HUE069263T2 (hu) 2022-03-17 2025-02-28 Gilead Sciences Inc Ikarosz cink-ujj család degradálói és azok alkalmazása
IL316032A (en) 2022-04-08 2024-11-01 Regeneron Pharma Multicomponent receptor and signaling complexes
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
IL316250A (en) * 2022-05-02 2024-12-01 Tscan Therapeutics Inc Multiplexed T-cell receptor complexes, combination therapies and their uses
PE20250758A1 (es) 2022-07-01 2025-03-13 Gilead Sciences Inc Compuestos de cd73
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024123794A2 (en) * 2022-12-05 2024-06-13 Board Of Regents, The University Of Texas System A t cell receptor recognizing a her2 mutation presented on hla-a*02:01 and methods of use
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
CN116239700B (zh) * 2022-12-20 2024-06-21 浙江大学 一种肿瘤双靶向的三特异性t细胞衔接器及其应用
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
CN116284448B (zh) * 2023-02-14 2024-06-21 浙江大学 一种超抗原参与的三功能t细胞衔接器及其应用
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759243B2 (en) * 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6811785B2 (en) * 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
WO2003020763A2 (en) * 2001-08-31 2003-03-13 Avidex Limited Soluble t cell receptor
ATE417065T1 (de) 2004-05-19 2008-12-15 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor

Also Published As

Publication number Publication date
US20110038842A1 (en) 2011-02-17
EP1765860B1 (de) 2008-12-10
NZ550810A (en) 2009-05-31
DE602005011617D1 (de) 2009-01-22
US20180072788A1 (en) 2018-03-15
US20210061878A1 (en) 2021-03-04
JP4773434B2 (ja) 2011-09-14
CA2566363A1 (en) 2005-12-01
DK1765860T3 (da) 2009-03-09
CA2566363C (en) 2014-12-16
WO2005113595A2 (en) 2005-12-01
US20180371049A1 (en) 2018-12-27
US20110262414A1 (en) 2011-10-27
US9822163B2 (en) 2017-11-21
WO2005113595A3 (en) 2006-06-01
US8008438B2 (en) 2011-08-30
US8143376B2 (en) 2012-03-27
US20130058908A1 (en) 2013-03-07
US20160159881A1 (en) 2016-06-09
US9156903B2 (en) 2015-10-13
AU2005245664B2 (en) 2012-02-02
US20170088599A1 (en) 2017-03-30
US8367804B2 (en) 2013-02-05
US9512197B2 (en) 2016-12-06
AU2005245664A1 (en) 2005-12-01
EP1765860A2 (de) 2007-03-28
US20150231202A1 (en) 2015-08-20
US20110014169A1 (en) 2011-01-20
JP2008509090A (ja) 2008-03-27

Similar Documents

Publication Publication Date Title
ATE417065T1 (de) Hochaffiner ny-eso-t-zellen-rezeptor
IL221366A0 (en) SOLUBLE zB7RI POLYPEPTIDE AND METHOD USING IT
US20130149289A1 (en) T cell receptor mutants
WO2005116051A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
EP1778842B8 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
RU2016124280A (ru) Клетка
RU2016101711A (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
ATE527353T1 (de) Pdgf-bindendes polypeptid aus protein a
EA200601904A1 (ru) Система отсроченного высвобождения лекарственного средства на основе полимеров
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
EP3263585A3 (de) Foxm1-peptid und arzneimittel damit
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
WO2011044452A3 (en) Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
NO20064134L (no) Modifiserte bouganinproteiner, cytotoksiner og fremgangsmater og anvendelser derav
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
RU2011121971A (ru) Пептиды-производные ил-4 для модуляции хронического воспалительного ответа и лечения аутоиммунных заболеваний
WO2012012531A3 (en) Compositions and methods featuring il-6 and il-21 antagonists
RU2016107873A (ru) Пептиды
JP2018522061A5 (de)
KR102456666B1 (ko) ＨＬＡ-Ｂ５７ 개방 이형태체(open conformer)
CN107223133A (zh) 一种可溶的异质二聚t细胞受体及其制法和应用
Nishimura et al. Modification of human T-cell responses by altered peptide ligands: a new approach to antigen-specific modification
WO2006125963A3 (en) Modified leukocyte ig-like receptor family members (lir' s) with increased affinity for class i mhc and their uses in modulating t cell activation
EA200700990A1 (ru) Новые пептиды, которые связывают рецептор эритропоэтина

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties